Interaction of tau with the RNA-Binding Protein TIA1 Regulates tau Pathophysiology and Toxicity
Tara Vanderweyde,
Daniel J. Apicco,
Katherine Youmans-Kidder,
Peter E.A. Ash,
Casey Cook,
Edroaldo Lummertz da Rocha,
Karen Jansen-West,
Alissa A. Frame,
Allison Citro,
John D. Leszyk,
Pavel Ivanov,
Jose F. Abisambra,
Martin Steffen,
Hu Li,
Leonard Petrucelli,
Benjamin Wolozin
Affiliations
Tara Vanderweyde
Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA
Daniel J. Apicco
Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA
Katherine Youmans-Kidder
Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA
Peter E.A. Ash
Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA
Casey Cook
Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
Edroaldo Lummertz da Rocha
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Karen Jansen-West
Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
Alissa A. Frame
Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA
Allison Citro
Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA
John D. Leszyk
Department of Biochemistry and Molecular Pathology, University of Massachusetts Medical School, Shrewsbury, MA 01545, USA
Pavel Ivanov
Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA 02115, USA
Jose F. Abisambra
Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40506, USA
Martin Steffen
Department of Pathology and Laboratory Medicine, Boston University, Boston, MA 02118, USA
Hu Li
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Leonard Petrucelli
Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
Benjamin Wolozin
Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA; Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA; Corresponding author
Summary: Dendritic mislocalization of microtubule associated protein tau is a hallmark of tauopathies, but the role of dendritic tau is unknown. We now report that tau interacts with the RNA-binding protein (RBP) TIA1 in brain tissue, and we present the brain-protein interactome network for TIA1. Analysis of the TIA1 interactome in brain tissue from wild-type (WT) and tau knockout mice demonstrates that tau is required for normal interactions of TIA1 with proteins linked to RNA metabolism, including ribosomal proteins and RBPs. Expression studies show that tau regulates the distribution of TIA1, and tau accelerates stress granule (SG) formation. Conversely, TIA1 knockdown or knockout inhibits tau misfolding and associated toxicity in cultured hippocampal neurons, while overexpressing TIA1 induces tau misfolding and stimulates neurodegeneration. Pharmacological interventions that prevent SG formation also inhibit tau pathophysiology. These studies suggest that the pathophysiology of tauopathy requires an intimate interaction with RNA-binding proteins. : Vanderweyde et al. show that the interaction of microtubule associated protein tau with the RNA binding protein (RBP) TIA1 regulates stress granule (SG) formation as well as misfolding and aggregation of tau. TIA1 knockdown prevents tau misfolding and tau-mediated toxicity, which points to RBPs as potential targets for therapy of tauopathies.